Reduced gap junction (GJ) coupling and muscle loss caused by unregulated opening of Cx43 hemichannels (HCs) in the acute phase following a myocardial infarction are thought to contribute to formation of an arrhythmic substrate. In the previous period, we showed that a mimetic peptide corresponding to the PDZ-binding domain of Cx43 (?CT1) preserved action potential conduction properties, reduced arrhythmias and improved contractile function following myocardial injury. We further demonstrated that the mechanism of ?CT1 involved inhibition of interaction between Cx43 and ZO-1 in a membrane microdomain adjacent to the GJ - the perinexus. Inhibition of Cx43:ZO-1 interaction prompted release of HCs from the perinexus and their sequestration into GJs- thus inhibiting hemichannel activity. ?CT1 was also found to increase phosphorylation at a PKC? site on Cx43 at serine 368 (S368). In new data, we show that ?CT1 prompts this Cx43 modification via a novel mechanism that involves induction of distinct phosphorylated nanodomains within GJs. Moreover, in a collaborative study we determined that ?CT1 binds to the Cx43 loop domain. Importantly, the minimal sequence required for this interaction corresponds to that of Gap19 - another Cx43 mimetic peptide reported to inhibit hemichannels. Based on the newly identified interaction between Gap19 and the Cx43 PDZ-binding domain we propose the hypothesis that the mechanism of Gap19 also involves targeting of Cx43:ZO-1 interaction and is complementary to that of ?CT1. Namely, that Gap19 interacts with the Cx43 CT obstructing its engagement with the PDZ2 domain of ZO-1 - as opposed to ?CT1, which binds to PDZ2 thereby blocking Cx43 CT interaction. In this renewal we aim to: 1) Identify the molecular determinants of ?CT1-induced phosphorylation of Cx43 at serine 368 - a post-translational modification that inhibits HC activity and determine the degree to which S368 phosphorylation explains HC inhibition by ?CT1 and Gap19; 2) Determine whether Cx43 HC inhibitors spare heart muscle and prevent formation of an arrhythmic substrate if given in the acute hours following myocardial infarction; and 3) Determine whether a common aspect of ?CT1 and Gap19 mechanism is that both peptides prompt selective inhibition of hemichannel activity via disruption of Cx43:ZO-1 interactions in the perinexus. The tools used will include state-of-the- art super-resolution microscopy and functional MRI approaches, new rationally designed ?CT1 variants and novel cell lines and transgenic mouse models expressing a phospho-null S368A mutation. Progress from the previous funding period included publication of results from two Phase II clinical trials on ?CT1. The studies proposed herein will provide mechanistic understanding of new drugs targeting connexins and studies in animals that provide a necessary prelude to clinical testing of these drugs in humans as muscle-sparing and anti-arrhythmic therapies in the critical hours following a myocardial infarction.

Public Health Relevance

Ischemic heart disease is a leading cause of death in the USA and many of the deaths from this disease result from arrhythmias caused by muscle loss that occurs following a myocardial infarct. This loss of heart muscle can be made worse by clinical interventions such as angioplasty that restore blood flow following myocardial infarction. In this project we will explore the function and potential pharmacology of an important new therapeutic target in myocardial infarct, reperfusion injury and arrhythmia - the Cx43 hemichannel.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL056728-17
Application #
9619342
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Balijepalli, Ravi C
Project Start
1997-07-01
Project End
2019-12-31
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
17
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Virginia Polytechnic Institute and State University
Department
Miscellaneous
Type
Organized Research Units
DUNS #
003137015
City
Blacksburg
State
VA
Country
United States
Zip Code
24061
Hoagland, Daniel T; Santos, Webster; Poelzing, Steven et al. (2018) The role of the gap junction perinexus in cardiac conduction: Potential as a novel anti-arrhythmic drug target. Prog Biophys Mol Biol :
Lindsey, Merry L; Bolli, Roberto; Canty Jr, John M et al. (2018) Guidelines for experimental models of myocardial ischemia and infarction. Am J Physiol Heart Circ Physiol 314:H812-H838
Grek, Christina L; Sheng, Zhi; Naus, Christian C et al. (2018) Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. Curr Opin Pharmacol 41:79-88
Montgomery, Jade; Ghatnekar, Gautam S; Grek, Christina L et al. (2018) Connexin 43-Based Therapeutics for Dermal Wound Healing. Int J Mol Sci 19:
Raisch, Tristan B; Yanoff, Matthew S; Larsen, Timothy R et al. (2018) Intercalated Disk Extracellular Nanodomain Expansion in Patients With Atrial Fibrillation. Front Physiol 9:398
Veeraraghavan, Rengasayee; Hoeker, Gregory S; Alvarez-Laviada, Anita et al. (2018) The adhesion function of the sodium channel beta subunit (?1) contributes to cardiac action potential propagation. Elife 7:
Obert, Elisabeth; Strauss, Randy; Brandon, Carlene et al. (2017) Targeting the tight junction protein, zonula occludens-1, with the connexin43 mimetic peptide, ?CT1, reduces VEGF-dependent RPE pathophysiology. J Mol Med (Berl) 95:535-552
Grek, Christina L; Montgomery, Jade; Sharma, Meenakshi et al. (2017) A Multicenter Randomized Controlled Trial Evaluating a Cx43-Mimetic Peptide in Cutaneous Scarring. J Invest Dermatol 137:620-630
Jiang, Jingbo; He, Huamei; Gourdie, Robert G et al. (2017) [Ischemia/reperfusion injury study in isolated mouse hearts using a pressure-volume curve]. Zhonghua Yi Xue Za Zhi 97:2691-2696
George, Sharon A; Calhoun, Patrick J; Gourdie, Robert G et al. (2017) TNF? Modulates Cardiac Conduction by Altering Electrical Coupling between Myocytes. Front Physiol 8:334

Showing the most recent 10 out of 64 publications